Table 2.
Clinical features at baseline
| Age, years (mean, range) | 83, 66-96 |
|---|---|
| Sex n (%) | |
| Female | 17 (59%) |
| Male | 12 (41%) |
| Visual acuity, logMAR (mean, range) | 1.85, 0.8–2.3 |
| Fellow eye visual acuity | 0.94, 0.2–2.3 |
| Duration of symptoms, days n (%) | |
| 1–7 | 19 (66%) |
| 8–13 > 14 | 3 (10%) 7 (24%) |
| Size of SMH, DD n (%) | |
| 2–6 | 9 (31%) |
| 7–11 | 11 (38%) |
| 12–16 | 3 (10%) |
| > 16 | 6 (21%) |
| Known ocular co-morbidity of affected eye n (%) | |
| None | 13 (45%) |
| Dry AMD | 8 (28%) |
| nAMD | 7 (24%) |
| OHT | 1 (3%) |
| Lens status n (%) | |
| Phakic | 20 (69%) |
| Pseudophakic | 9 (31%) |
| Initial treatment n (%) | |
| Observation | 6 (21%) |
| IVT aflibercept | 1 (3%) |
| IVT ranibizumab | 5 (17%) |
| PPV/ SRET tPA and ranibizumab/gas | 17 (58%) |
| Time to treatment (days) mean (range) | |
| Anti-VEGF | 38 (6–55) |
| Vitrectomy | 3 (0-6) |
| Overall | 10 (0-55) |
AMD age-related macular degeneration, DD disc diameter, IVT intravitreal, nAMD neovascular age-related macular degeneration, SMH submacular haemorrhage, SRET subretinal, PPV pars plana vitrectomy, VA visual acuity. N = 29 for all values